ArticleArthritis research & therapy2025
Clinical features, treatment, and outcome of isotretinoin-associated sacroiliitis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Timing of Isotretinoin Exposure and Early Postoperative Complications after Anterior Cruciate Ligament Reconstruction.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026Article
- Case Report: Sacroiliitis and Long-Term Effects on Bones and Joints Following Isotretinoin Use.International journal of rheumatic diseases · 2026Article
- Sex- and age-specific musculoskeletal adverse events of isotretinoin: disproportionality analysis of the FAERS database combined with a clinical case series.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSacroiliitis is a rare adverse reaction of isotretinoin. However, the data on the clinical features, treatment and outcomes of isotretinoin-associated sacroiliitis are limited. This study was conducted to explore the clinical characteristics of isotretinoin-associated sacroiliitis, providing a basis for diagnosis and treatment.
methodsThe author retrieved clinical reports of isotretinoin-associated sacroiliitis from the database for a retrospective analysis up to March 31, 2025.
resultsA total of 67 patients were included, with a median age of 21 years (range 14, 44). Fifty-six (83.6%) of the patients were from Turkey. The median time of sacroiliitis was 2.5 months (range 0.4, 24) after isotretinoin administration. Low back pain (70.1%) and hip pain (44.8%) are the main symptoms of patients with sacroiliitis. Magnetic resonance imaging (MRI) mainly showed sacroiliitis (73.1%) and bone marrow edema (34.3%). After discontinuation of isotretinoin and treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and biologics, the patient's symptoms and MRI improved.
conclusionPatients treated with isotretinoin who experience low back pain should consider the possibility of sacroiliitis. MRI is a useful tool for the diagnosis of sacroiliitis. The cessation of isotretinoin therapy, coupled with the administration of NSAIDs, can effectively alleviate the symptoms experienced by patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.